Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

Phase 2

Completed

Conditions: Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris

Interventions: Drug: secukinumab 300 mg Q2W
Drug: secukinumab 300 mg Q4W
Other: Placebo

First Posted Date: 2020-03-09

Last Posted Date: 2023-08-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT04300296

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Terminated

Conditions: Plasmodium Falciparum Malaria

First Posted Date: 2020-03-09

Last Posted Date: 2024-11-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT04300309

Locations: 🇨🇩
Novartis Investigative Site, Kisantu, Bas Kongo, Congo, The Democratic Republic of the

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Phase 1

Terminated

Conditions: BRAF V600 Colorectal Cancer

Interventions: Drug: Dabrafenib
Drug: LTT462
Drug: LXH254
Drug: TNO155
Drug: Trametinib
Biological: Spartalizumab
Biological: Tislelizumab

First Posted Date: 2020-03-03

Last Posted Date: 2024-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT04294160

Locations: 🇺🇸
University of California LA Santa Monica Location, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute SC, Nashville, Tennessee, United States

and more 2 locations

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

Completed

Conditions: PIK3CA-Related Overgrowth Spectrum (PROS)

Interventions: Other: alpelisib

First Posted Date: 2020-02-26

Last Posted Date: 2023-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT04285723

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain
🇺🇸
Boston Childrens Hospital, Boston, Massachusetts, United States

Study of Select Combinations in Adults With Myelofibrosis

Phase 1

Withdrawn

Conditions: Primary Myelofibrosis
Myelofibrosis
PMF
Post-Essential Thrombocythemia Myelofibrosis
Post-Polycythemia Vera Myelofibrosis

Interventions: Drug: MBG453
Drug: NIS793
Drug: Decitabine
Drug: Spartalizumab

First Posted Date: 2020-02-25

Last Posted Date: 2021-03-04

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04283526

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Phase 3

Completed

Conditions: Proliferative Diabetic Retinopathy

Interventions: Procedure: Panretinal photocoagulation laser
Biological: Brolucizumab 6 mg

First Posted Date: 2020-02-20

Last Posted Date: 2024-10-02

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 689

Registration Number: NCT04278417

Locations: 🇺🇸
Retina- Vitreous Assoc Medical Group ., Beverly Hills, California, United States
🇺🇸
Retina Associates SW, Tucson, Arizona, United States
🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States

and more 30 locations

Clinical Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Terminated

Conditions: Chronic Obstructive Pulmonary Disease

Interventions: Drug: Placebo
Drug: QBW251

First Posted Date: 2020-02-13

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT04268823

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic

Interventions: Drug: Sabatolimab
Drug: Azacitidine
Drug: Placebo

First Posted Date: 2020-02-12

Last Posted Date: 2024-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 530

Registration Number: NCT04266301

Locations: 🇺🇸
University Of Miami, Miami, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 9 locations

Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age-Related Macular Degeneration

Interventions: Drug: RTH258/Brolucizumab

First Posted Date: 2020-02-11

Last Posted Date: 2024-11-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 295

Registration Number: NCT04264819

Locations: 🇫🇷
Novartis Investigative Site, Vincennes, France

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

Phase 1

Terminated

Conditions: In Escalation: All Patients With Solid Tumors and Lymphoma
In Expansion: Melanoma, Non-small Cell Lung Cancer

Interventions: Drug: NIZ985
Drug: Spartalizumab
Drug: Tislelizumab

First Posted Date: 2020-02-07

Last Posted Date: 2024-01-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT04261439

Locations: 🇺🇸
City of Hope National Medical, Duarte, California, United States
🇺🇸
Moores UCSD Cancer Center, La Jolla, California, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy